コンテンツへスキップ
Merck
  • Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.

Bioorganic & medicinal chemistry letters (2009-03-24)
Tsutomu Akama, Stephen J Baker, Yong-Kang Zhang, Vincent Hernandez, Huchen Zhou, Virginia Sanders, Yvonne Freund, Richard Kimura, Kirk R Maples, Jacob J Plattner
要旨

A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. This compound is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
デキサメタゾン, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
デキサメタゾン, ≥98% (HPLC), powder
Sigma-Aldrich
デキサメタゾン, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
デキサメタゾン, meets USP testing specifications
Sigma-Aldrich
クリサボロール, ≥98% (HPLC)
Sigma-Aldrich
デキサメタゾン, tested according to Ph. Eur.
Supelco
デキサメタゾン, VETRANAL®, analytical standard